SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Royce Biomedical (RYBO-BB) - any thoughts?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Neil_98 who wrote (36)7/23/1998 2:10:00 PM
From: Rob   of 42
 
Neil. First, thank you for your professional reply. You have helped to provide me with some clarity. If you don't mind I have a few more comments and questions.

Response's test is also very user friendlyhowever because of the cost of the reader will be marketed for self-monitoring for home users once diagnosed where quantitative accuracy is required. Response's reader costs $1000 but test strips are only a few $. The science is rapid, quantitative and as accurate and sensitive as ELISSA standards giving it a huge advantage over more expensive lab tests. Response's tests will therefore be primarily marketed to the medical community to replace laboratory tests.

The prime differentiators appear to be that (1) Royce's product is qualitative (e.g.- One red dot - Negative, Two red dots - Positive) vs Response's which is quantitative; (2) Your advantage appears to be that your test does not require a $1000 reader and is therefore affordable for initial self-diagnosis where quantitative results are not required.

It appears to make sense to use your product for initial self-diagnosis because it is inexpensive and then Respnse's test for ongoing monitoring depending on the accuracy required of the test being conducted.

Bottom line, it does not look like you are in direct competition for the same customers. Is this an accurate assessment?

Regarding Royce - what exactly is its competitive advantage against other qualitative self / point-of-care diagnostic tests? That it
- can be used to perform rapid qualitative tests for analytes currently not possible with other self-diagnosis science?
- is more accurate and sensitive than already existing qualitative self-diagnostic tests?
- is cheaper than already existing qualitative self-diagnostic tests?

Thank you Neil for taking the time to reply. I hope this is as useful for providing clarity for your investors as it is for myself.

Best regards,

Rob

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News